This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|February 6, 2019
Meissner Announces New Manufacturing Facility
Author(s)BioPharm International Editors
The company will open its first European manufacturing facility in Castlebar, Ireland.
Advertisement
On Feb. 1, 2019, Meissner Filtration Products, a developer, manufacturer, and supplier of microfiltration and single-use systems, announced plans to establish a new manufacturing facility in County Mayo, Ireland.
Meissner will expand an existing 34,000-ft2 advanced technology building constructed by the Industrial Development Authority (IDA) Ireland in Castlebar to 100,000 ft2. The company has also purchased the adjacent land to more than triple the facility’s current footprint, and plans to install a large, state-of-the-art cleanroom within the existing facility to be used for the manufacture of single-use systems (SUS). The new facility is expected to be operational in the first quarter of 2020. Initial operations will include SUS manufacturing, quality and regulatory, engineering, and customer service.
“We have seen substantial growth in our SUS portfolio over the past 10 years, and ensuring we have capacity in excess of customer demand is critical,” stated Christopher Meissner, CEO of Meissner Filtration Products, in a company press release. “Additionally, we acutely recognize the value of manufacturing proximate to our customer base as well as geographically diversifying our manufacturing footprint.”
Currently, Meissner has a manufacturing campus in Camarillo, CA, and a European logistics hub outside of Frankfurt, Germany. The company reports that the Castlebar facility will be its first manufacturing facility in Europe, creating over 150 jobs over the next five years.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5